More about

Abiraterone Acetate

News
October 12, 2024
2 min read
Save

Enzalutamide confers small benefit vs. abiraterone in metastatic prostate cancer

Enzalutamide confers small benefit vs. abiraterone in metastatic prostate cancer

Enzalutamide conferred small but statistically significant improvements in outcomes vs. abiraterone acetate for men with metastatic castration-resistant prostate cancer, according to retrospective study results.

News
September 24, 2023
1 min read
Save

Prostate Cancer Awareness Month: Financial hardship common, exercise beneficial

Prostate Cancer Awareness Month: Financial hardship common, exercise beneficial

National Prostate Cancer Awareness Month is observed every September.

News
July 07, 2023
2 min read
Save

Mark Cuban company could yield savings on seven Medicare generic oncology drugs

Mark Cuban company could yield savings on seven Medicare generic oncology drugs

Mark Cuban Cost Plus Drug Company’s pricing could yield significant savings for seven generic oncology drugs vs. Medicare Part D median formulary prices, according to study results published in Journal of Clinical Oncology.

News
July 06, 2023
3 min read
Save

Recent developments in advanced prostate cancer space pave way for future breakthroughs

Recent developments in advanced prostate cancer space pave way for future breakthroughs

Several practice-changing clinical trials in recent years have led to the understanding that combination treatments are most effective for patients with advanced prostate cancer.

News
June 18, 2023
3 min read
Save

Radiation plus intensive systemic therapy improves outcomes in prostate cancer subset

Radiation plus intensive systemic therapy improves outcomes in prostate cancer subset

CHICAGO Adding prostate irradiation to standard systemic therapy extended radiographic PFS among men with newly diagnosed low-volume metastatic castration-sensitive prostate cancer, according to results of the PEACE-1 trial.

News
June 01, 2023
1 min read
Save

FDA approves Lynparza regimen for certain men with BRCA-positive prostate cancer

FDA approves Lynparza regimen for certain men with <i>BRCA</i>-positive prostate cancer

The FDA approved olaparib in combination with abiraterone acetate and prednisone or prednisolone for men with suspected deleterious or deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

News
April 28, 2023
3 min read
Save

FDA committee favors restricting prostate cancer regimen to BRCA-positive subgroup

FDA committee favors restricting prostate cancer regimen to <i>BRCA</i>-positive subgroup

An FDA advisory committee recommended that a proposed indication for olaparib with abiraterone acetate as first-line treatment for metastatic castration-resistant prostate cancer be limited to patients whose tumors have BRCA mutations.

News
February 18, 2023
4 min read
Save

Niraparib regimen improves outcomes for men with prostate cancer, HRR gene alterations

Niraparib regimen improves outcomes for men with prostate cancer, HRR gene alterations

SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved multiple outcomes for certain men with metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.

News
February 16, 2023
2 min read
Save

Rucaparib improves radiographic PFS in prostate cancer subgroup

Rucaparib improves radiographic PFS in prostate cancer subgroup

SAN FRANCISCO — Rucaparib significantly improved radiographic PFS compared with physician’s choice of therapy for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.

News
October 08, 2022
2 min read
Save

Rucaparib extends PFS in advanced prostate cancer

Rucaparib extends PFS in advanced prostate cancer

A randomized phase 3 trial that assessed rucaparib for certain men with advanced prostate cancer met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.

View more